Abstract:Abstract The association between Alzheimer’s disease (AD) and lower cancer incidence has been observed in several epidemiological studies without much mechanistic insight. We aimed to understand this cancer resistance mechanism linked to AD and exploit it for broader cancer therapies. A hallmark of AD is the accumulation of amyloid precursor protein (APP) in neuronal mitochondria, inhibiting mitophagy, abrogating the clearance of dysfunctional mitochondria, and contributing to AD pathology. In addition to neurons, mitophagy plays an important role in T-cells, where excessive ceramide-dependent mitophagy in aging T-cells inhibits their energy metabolism and limits their anti-tumor functions. Thus, attenuation of ceramide-dependent mitophagy plays a favorable role in enhancing aging T-cell anti-tumor function. Given that APP is also processed in T-cells, we hypothesized that APP accumulates aberrantly in aging Alzheimer’s T-cells, inhibiting mitophagy and enhancing T-cell anti-tumor activity. Employing techniques of lipidomics, metabolomics, imaging, molecular biology, and genetic models, we show that AD T-cells from a mouse model and human patients are protected against aging-associated ceramide-dependent mitophagy, which enhanced their secretion of inflammatory anti-tumor cytokines. The excessive localization of APP to the T-cell mitochondria, where it inhibits the accumulation of ceramide synthase 6 (CerS6) and C14/C16-ceramides, attenuated the levels of mitophagy and protected the Alzheimer’s T-cells from metabolic defects observed in aging, namely protecting against the exhaustion of fumarate pools. Both in vitro and in vivo re-supplementation of fumarate to aging WT mouse T-cells effectively rescued their viability, cytokine production, and tumor killing capacity both in vitro and in adoptive T-cell transfers to mice with melanoma, functionally mimicking the AD phenotype. The fumarate supplementation also led to a decrease in ceramide-dependent mitophagy in the WT aging T-cells, indicating an interplay between ceramide-dependent mitophagy and fumarate metabolism which contributes to the protection of the anti-tumor function in aging AD T-cells. Moreover, we show that Alzheimer’s mice that express APP in the brain and T-cells, but not AD mice that express APP only in the brain, are protected against the growth of both carcinogen-induced and allografted tumors. Finally, transfer of mitochondria from AD T-cells to aging WT T-cells improved their metabolic fitness and anti-cancer functions. In summary, we show that AD-associated APP improves anti-tumor immunity of aging T-cells by inhibiting ceramide-mediated lethal mitophagy and restoring mitochondrial fumarate metabolism. These data provide a novel mechanism to explain reduced cancer incidences in AD patients. Citation Format: Mohamed Faisal Kassir, Han G. Lee, Natalia Oleinik, Wyatt Wofford, Chase Walton, F. Cansu Atilgan, Paramita Chakraborty, Kubra Calisir, Ozgur Sahin, Shikhar Mehrotra, Besim Ogretmen. Alzheimer's disease-associated amyloid precursor protein improves anti-tumor immunity by inhibiting ceramide-mediated lethal mitophagy and restoring mitochondrial fumarate metabolism in aging T-cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3969.

Abstract 2867: Ceramide-dependent mitophagy leads to metabolic reprogramming in aging T-cells associated with reduced anti-tumor T-cell functions

Aging-dependent Mitochondrial Dysfunction Mediated by Ceramide Signaling Inhibits Antitumor T Cell Response

Abstract 3969: Alzheimer's disease-associated amyloid precursor protein improves anti-tumor immunity by inhibiting ceramide-mediated lethal mitophagy and restoring mitochondrial fumarate metabolism in aging T-cells

Abstract 2688: Age-associated changes in macrophage function and phenotype affects cancer development, and the efficacy of macrophage targeted anticancer therapies in murine melanoma model

Metabolic Reprogramming Induced by Aging Modifies the Tumor Microenvironment

Abstract 6592: Deciphering the effects of age on T cell immunity and immunotherapy

Abstract 851: Uncovering a novel role of succinate metabolism in tregulatory cells of aged epithelial ovarian cancer mice

Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients

Abstract 358: Ferroptosis modulates melanoma progression in an age-specific manner through changes in the tumor microenvironment

Tumor-produced and aging-associated oncometabolite methylmalonic acid promotes cancer-associated fibroblast activation to drive metastatic progression

Inhibiting de novo ceramide synthesis restores mitochondrial and protein homeostasis in muscle aging

Suppressed basal mitophagy drives cellular aging phenotypes that can be reversed by a p62-targeting small molecule

Abstract A003: The role of aging in promoting immune mediated reactivation from metastatic melanoma dormancy

Abstract 3921: The aged tumor microenvironment limits CD8+ T cell control of cancer

Abstract A043: Senescent CAFs modulate tumor immunity and promote breast cancer progression

Targeting cellular senescence in metabolic disease

Methylmalonic acid induces metabolic abnormalities and exhaustion in CD8 + T cells to suppress anti-tumor immunity

Methylmalonic acid induces metabolic abnormalities and exhaustion in CD8 T cells to suppress anti-tumor immunity

Abstract 2961: Investigating the role of aging and treatment-induced senescence in the metastatic liver cancer tumor microenvironment

Abstract 268: Antitumor CD4+ T Cells Reprogram Tumor Metabolism to Drive Progressive Tumor Regression

Abstract 4282: Crosstalk between the immune system and the extracellular matrix in the context of melanoma and aging